RxDoctor Payments Data

Maria Martin, MD

Family Medicine · Silver Spring, MDNPI 1568634590

Payments from drug & device makers

$3,900in general payments, 2019–2025

Across 222 payments — averaging $17.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$1K
  • Viiv Healthcare Company$926
  • Johnson & Johnson$420
  • Amgen$227
  • AbbVie$221
  • Merck$191
  • plus $486 from 12 others

What the payments were for

  • Speaking & faculty fees$180%
  • Food & beverage$3,85499%
  • Education$281%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,900 in reported general payments places this provider in the 85th percentile of 1,193 family medicine providers in Maryland.

See all family medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$19,224
Medicare patients
40
Services billed
153

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala33$129,245
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf24$113,860
DovatoDolutegravir Sodium/Lamivudine22$71,076
RybelsusSemaglutide20$49,004
JardianceEmpagliflozin16$28,213
TrulicityDulaglutide20$25,004
JanuviaSitagliptin Phosphate14$18,959
SymbicortBudesonide/Formoterol Fumarate15$3,552
Ezetimibe17$1,018
Gabapentin29$800
Chlorthalidone25$788
Atorvastatin Calcium137$733
Azelastine Hcl12$686
Tamsulosin Hcl48$508
Lisinopril84$499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$1,429$129,24533 claims
Viiv Healthcare CompanyDovato$926$71,07622 claims
Novo NordiskRybelsus$46$49,00420 claims
Lilly USA, LLCTrulicity$141$25,00420 claims
MerckJanuvia$191$18,95914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,193 family medicine providers in Maryland.

Other family medicine in Silver Spring

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →